Featured Research

from universities, journals, and other organizations

Yale Researchers Develop New Molecule That Eradicates Cancer By Destroying Tumor Blood Vessels

Date:
November 2, 2001
Source:
Yale University
Summary:
Researchers at Yale have developed a new molecule they call "icon" that targets blood vessels in tumors for destruction by the immune system without harming vessels in normal tissues.

Researchers at Yale have developed a new molecule they call "icon" that targets blood vessels in tumors for destruction by the immune system without harming vessels in normal tissues.

"Our study resulted in the eradication of injected tumors and also of other tumors in mice that had not been injected," said principal investigator Alan Garen, professor of molecular biophysics and biochemistry at Yale University. "This serves as a model of metastatic cancer. None of the normal tissues in the mouse appeared to be harmed by our procedure."

Published in the October 9 issue of Proceedings of the National Academy of Sciences, the study was conducted with human melanoma and prostate tumors growing in mice. The gene for the icon was inserted into an adenovirus vector that was injected into a tumor, resulting in the infection of tumor cells that act within the mice as factories for producing the icon and secreting it into the blood.

Garen said that in order to target tumor blood vessels without harming the normal blood vessels, a molecule that is expressed specifically on the inner surface of the tumor is needed. The molecule used for this study is called tissue factor, whose normal function is to initiate blood clotting.

Blood clotting occurs when another molecule called factor VII, which circulates constantly in the blood, binds to tissue factor. The binding of factor VII to tissue factor is one of the strongest and most specific interactions known in biology. Garen and Yale research scientist Zhiwei Hu, constructed the icon, which is modeled after a camel's version of an antibody. The icon is composed of two parts. One part targets the icon to tissue factor by using factor VII as the targeting domain. The other part of the icon is the region of a natural antibody that activates an attack by the immune system against cells that bind to the icon.

"The result is that the tumor blood vessels are destroyed by the immune system and consequently the tumor cells die because they lack a blood supply," said Garen. "The normal blood vessels survive because they do not express tissue factor and therefore do not bind the icon."

"This icon should work against all types of tumors that contain blood vessels," said Garen. "The icon that will be used in a clinical trial is derived entirely from human components and therefore should not be significantly immunogenic, which is an advantage over antibodies used in this kind of study."

Garen said the procedure could also be effective against other diseases that require growing blood vessels, such as macular degeneration, the major cause of blindness in older people.

A clinical trial is being arranged by Albert Deisseroth, M.D., formerly of Yale, and currently President of the Sidney Kimmel Cancer Center in San Diego.

The study was funded in part by the National Institutes of Health and by gifts from private donors.


Story Source:

The above story is based on materials provided by Yale University. Note: Materials may be edited for content and length.


Cite This Page:

Yale University. "Yale Researchers Develop New Molecule That Eradicates Cancer By Destroying Tumor Blood Vessels." ScienceDaily. ScienceDaily, 2 November 2001. <www.sciencedaily.com/releases/2001/11/011101061604.htm>.
Yale University. (2001, November 2). Yale Researchers Develop New Molecule That Eradicates Cancer By Destroying Tumor Blood Vessels. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2001/11/011101061604.htm
Yale University. "Yale Researchers Develop New Molecule That Eradicates Cancer By Destroying Tumor Blood Vessels." ScienceDaily. www.sciencedaily.com/releases/2001/11/011101061604.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins